FINWIRES · TerminalLIVE
FINWIRES

Palantir and Anthropic More Complementary Than Competitive in Enterprise AI, Oppenheimer Says

By

Palantir Technologies (PLTR) and Amazon-backed (AMZN) Anthropic are better viewed as complementary players rather than direct competitors in the enterprise AI ecosystem, as they operate at different layers of the technology stack and serve distinct types of workloads, Oppenheimer said in a Thursday note.

Palantir is positioned for complex, customized enterprise workflows via its ontology-based platform, while Anthropic is better suited for simpler automation tasks relying on frontier model capabilities without deep integration, the analysts said.

Oppenheimer also highlighted existing collaborations between Palantir and Anthropic, including the integration of Anthropic's Claude models within Palantir's AI Platform, suggesting their relationship is more likely to remain collaborative than become competitive.

The enterprise AI total addressable market continues to expand for both companies, with Palantir focused on large-scale, complex enterprise deployments and Anthropic targeting broader automation use cases across enterprises, SMBs, and global markets, according to the report.

Oppenheimer maintained an outperform rating on Palantir with a price target of $200.

Palantir shares were up 0.5% in Thursday trading.

Price: $142.33, Change: $+0.13, Percent Change: +0.09%

Related Articles

Wire

Tyler Technologies Expected to Reaffirm 2030 Revenue Guidance, Oppenheimer Says

Tyler Technologies (TYL) is likely to reaffirm its 2030 revenue target of $3.6 billion to $3.8 billion at its June 9 investor day, with potential upward revisions to EBIT and free cash flow margin targets, Oppenheimer said in a note Thursday.The company is also expected to reaffirm its cloud transition strategy through 2030, which is supporting revenue quality and SaaS durability, according to the note.The brokerage said management is likely to highlight AI tailwinds, but it does not expect explicit AI revenue contribution given nascent adoption.Oppenheimer has an outperform rating on the stock, with a price target of $450 per share.Shares of Tyler Technologies were up 3% in Thursday trading.Price: $312.94, Change: $+9.17, Percent Change: +3.02%

$TYL
Wire

C3.ai Turnaround Still Unclear as Revenue Drops for Fourth Straight Quarter, Morgan Stanley Says

C3.ai (AI) turnaround remains uncertain as the company faced continued business deterioration in fiscal Q4, Morgan Stanley said Thursday in a report.The company on Wednesday reported a Q4 adjusted loss of $0.33 per diluted share, compared with the loss of $0.16 a year earlier, as revenue fell to $51.6 million from $108.7 million. C3.ai projected $50 million to $54 million in revenue for Q1 and $210 million to $240 million for fiscal 2027.Morgan Stanley said the Q4 results were in line with C3.ai's outlook while marking the fourth straight quarter of revenue decline. The fiscal 2027 revenue outlook implies a 10% drop at the midpoint, the report said.Management attributed the sales issues to "substandard" execution that can be fixed while providing few details on its turnaround strategy, the report said.Morgan Stanley raised its price target on C3.ai stock to $7 from $6 and reiterated its underweight rating.Price: $10.63, Change: $-0.09, Percent Change: -0.79%

$AI
Wire

Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug.Vascepa received Food and Drug Administration approval in 2012 for treating severe hypertriglyceridemia before receiving the FDA's go-ahead in 2019 for a second, more common use: lowering cardiovascular risk in hypertriglyceridemia patients who take statins, the so-called CV indication, for which it received two patents, the Supreme Court noted.Hikma received FDA approval for a generic icosapent ethyl skinny label in 2020 that carves out Vascepa's still-patented CV-indication method of use, the court noted."Amarin has failed to state a claim for active inducement in violation of *271(b), so its complaint cannot withstand Hikma's motion to dismiss," the Supreme Court said.The companies didn't immediately reply to requests for comment from.Price: $14.59, Change: $+0.06, Percent Change: +0.41%

$AMRN